...
首页> 外文期刊>Brain & Development >Effects of low-dose hydrochlorothiazide on urolithiasis and bone metabolism in severely disabled individuals: a pilot study.
【24h】

Effects of low-dose hydrochlorothiazide on urolithiasis and bone metabolism in severely disabled individuals: a pilot study.

机译:低剂量氢氯噻嗪对重度残疾人的尿路结石和骨代谢的影响:一项初步研究。

获取原文
获取原文并翻译 | 示例

摘要

To clarify the effects of hydrochlorothiazide (HCT) on calcium metabolism in subjects with severe motor and intellectual disabilities (SMID), we examined four patients (16-48years old) with a history of urolithiasis and/or bone fracture and increased urinary calcium/creatinine ratio (U-Ca/Cr). U-Ca/Cr, blood markers of bone turnover, and bone-mineral density (BMD) were measured before and after administration of low-dose HCT (0.25-0.5mg/kg/day). Three months after the initiation of HCT, U-Ca/Cr decreased in all patients, but this effect was less evident at 9-18months. Bone-turnover marker of bone-specific alkaline phosphatase also showed a tendency to decrease, but BMD remained unchanged during the follow-up period. In SMID patients, HCT is beneficial for the treatment of hypercalciuria but its effects can be transient in certain cases. HCT may also ameliorate the increase in bone turnover, but its effects on the prevention of bone fractures remain uncertain. Hyponatremia is the most frequent and significant adverse effect of HCT, for which a close observation is mandatory in HCT application for patients with SMID.
机译:为了阐明氢氯噻嗪(HCT)对患有严重运动和智力障碍(SMID)的受试者钙代谢的影响,我们检查了四名具有尿路结石和/或骨折史且尿钙/肌酐升高的患者(16-48岁)比(U-Ca / Cr)。在服用低剂量HCT(0.25-0.5mg / kg / day)之前和之后测量U-Ca / Cr,骨转换的血液标志物和骨矿物质密度(BMD)。开始HCT后三个月,所有患者的U-Ca / Cr均下降,但在9-18个月时这种作用不明显。骨特异性碱性磷酸酶的骨转换标志物也表现出下降的趋势,但在随访期间BMD保持不变。在SMID患者中,HCT有助于治疗高钙尿症,但在某些情况下其作用可能是短暂的。 HCT也可以改善骨转换的增加,但是其对预防骨折的作用仍不确定。低钠血症是HCT最常见和最严重的不良反应,对于SMID患者,在应用HCT时必须严密观察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号